Resources

Access our latest resources—including publications about our science, recent media, and conference presentations.

Jun 2024 | From Ikena Oncology

A First In Human Study of IK-595, an Oral MEK/RAF Molecular Glue, In Patients with RAS- or RAF- Altered Advanced Solid Tumors

Nehal J. Lakhani, M.D., Ph.D. | ASCO Annual Meeting 2024

Sep 2023 | From Ikena Oncology

IK-595 Targeting MEK-RAF Complex to Overcome CRAF Mediated Resistance & Drive Superior Anti-Tumor Activity in RAS/RAF Altered Cancers

Michelle Zhang, Ph.D. | 5th Annual RAS-Targeted Drug Development Summit 2023

Apr 2023 | From Ikena Oncology

IK-930, a Paralog Selective TEAD Inhibitor Effectively Attenuates Drug-Tolerant Persister Cell Proliferation

Daniel Hidalgo, Ph.D. & Marta Sanchez-Martin, Ph.D. | AACR Annual Meeting 2023

Apr 2023 | From Ikena Oncology

IK-930, a TEAD Paralog Selective Inhibitor for Treating YAP/TAZ-TEAD Dependent Cancers

Nathan Young, Ph.D. & Marta Sanchez-Martin, Ph.D. | AACR Annual Meeting 2023

Mar 2023 | From Ikena Oncology

The Ah Receptor from Toxicity to Therapeutics. Report from the 5th AHR Meeting at Penn State University, USA, June 2022

McGovern, K et al. | International Journal of Molecular Sciences

Scroll to Top